Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
This strategic investment strengthens Cohance's integrated oligonucleotide platform
This strategic investment strengthens Cohance's integrated oligonucleotide platform
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
Vasograin Plus represents a major advancement in the treatment of migraine
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Subscribe To Our Newsletter & Stay Updated